EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021–2023

Ataru Igarashi, Shiro Tanaka, Raf De Moor, Nan Li, Mariko Hirozane, David Bin-Chia Wu, Li Wen Hong, Dae Young Yu, Mahmoud Hashim, Brian Hutton, Krista Tantakoun, Christopher Olsen und 3 weitere

Advances in Therapy · 2025

DOI: 10.1007/s12325-024-03013-6 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Therapy, 2025. Verfasst von Ataru Igarashi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Public Health and Preventive Medicine, Yokohama City University School of Medicine, Kanazawa Ward, Yokohama, Kanagawa, Japan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Approval, Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen Pharmaceutical K.K..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Indirect treatment comparisons (ITCs) evaluate novel treatments compared to appropriate comparators when direct evidence is unavailable or infeasible. The objective of this study was to highlight the prevalence of different ITC methods in oncology drug submissions and to provide insights into how ITCs have been used in recent regulatory approval, reimbursement recommendations, or pricing decisions across various regions and diverse assessment frameworks. METHODS: A targeted literature review was conducted to identify assessment documents for oncology drug submissions that included ITCs. This included hand searches of the websites of four regulatory bodies and four health technology assessment (HTA) agencies with varying assessment frameworks across North America, Europe, and Asia-Pacific. RESULTS: A total of 185 documents were included for synthesis. Documents were retrieved from all four HTA agencies and the European Medicines Agency (EMA), the only regulatory body with eligible records. Within these, 188 unique submissions included a total of 306 supporting ITCs of various methods. Authorities more frequently favored anchored or population-adjusted ITC techniques for their effectiveness in data adjustment and bias mitigation. Furthermore, ITCs in orphan drug submissions more frequently led to positive decisions compared to non-orphan submissions. CONCLUSIONS: This review highlights the crucial role and widespread use of ITCs in global healthcare decision-making, particularly when direct evidence is lacking, and in the discernment of market-specific clinical benefits. This work contributes to bolstering the credibility and recognition of ITCs across regulatory and HTA agencies of diverse regions and assessment frameworks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDrug ApprovalNeoplasmsHumansTechnology Assessment, BiomedicalDecision MakingReimbursement MechanismsDrug Costs

Stichwörter der Autor:innen

Health technology assessmentIndirect treatment comparisonPolicy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Unit of Public Health and Preventive Medicine, Yokohama City University School of Medicine, Kanazawa Ward, Yokohama, Kanagawa, Japan.
  • Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Value, Evidence and Access Department, IMAT, Janssen Pharmaceutical K.K., Tokyo, Japan.
  • Policy Department, IMAT, Janssen Pharmaceutical K.K., Tokyo, Japan.
  • Asia Pacific Regional Market Access, Janssen Pharmaceutical Companies of Johnson and Johnson, Singapore, Singapore.
  • Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.

ORCID-Profile: Chris Cameron

Förderung

  • Janssen Pharmaceutical K.K.

Zitieren

APA

Igarashi, A., Tanaka, S., De Moor, R., Li, N., Hirozane, M., Wu, D. B., Hong, L. W., Yu, D. Y., Hashim, M., Hutton, B., Tantakoun, K., Olsen, C., Fashami, F. M., Samjoo, I. A., & Cameron, C. (2025). Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021–2023. Advances in Therapy. https://doi.org/10.1007/s12325-024-03013-6

Vancouver

Igarashi A, Tanaka S, De Moor R, Li N, Hirozane M, Wu DB, et al. Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021–2023. Advances in Therapy. 2025. doi:10.1007/s12325-024-03013-6

BibTeX
@article{Igarashi2025,
  author = {Igarashi, Ataru and Tanaka, Shiro and De Moor, Raf and Li, Nan and Hirozane, Mariko and Wu, David Bin-Chia and Hong, Li Wen and Yu, Dae Young and Hashim, Mahmoud and Hutton, Brian and Tantakoun, Krista and Olsen, Christopher and Fashami, Fatemeh Mirzayeh and Samjoo, Imtiaz A and Cameron, Chris},
  title = {Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021–2023},
  journal = {Advances in Therapy},
  year = {2025},
  doi = {10.1007/s12325-024-03013-6}
}
Kostenlos starten →